PharmGen Science Stock

PharmGen Science EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of PharmGen Science (004720.KS) as of Aug 2, 2026 is 7.71. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 8.99 — a change of -14.25% (lower).

EV/EBIT

7.71

YoY

-14.25%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of PharmGen Science is 2026 7.71 . EV/EBIT (Enterprise Value to EBIT) of PharmGen Science was 2025 8.99 . It decreases by -14.25% lower compared to the previous year.

The PharmGen Science EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2017
20.95 base
Jan 1, 2018
17.81 base
Jan 1, 2019
64.40 base
Jan 1, 2020
-252.99 base
Jan 1, 2021
-38.76 base
Jan 1, 2022
19.30 base
Jan 1, 2023
14.13 base
Jan 1, 2024
8.37 base
YEARPRICE-TO-EBIT
2024 8.37
2023 14.13
2022 19.30
2021 -38.76
2020 -252.99
2019 64.40
2018 17.81
2017 20.95
2016 35.68
2015 13.33
2014 -12.37
2013 -9.49
2012 -9.70
2011 -6.48
2010 -49.85
2009 4.84
2008 2.80
2007 5.40
2006 3.52
2005 5.80
Access this data via the Eulerpool API
Get Free API Key

PharmGen Science Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides PharmGen Science's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates PharmGen Science's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots PharmGen Science's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if PharmGen Science grows earnings faster than its peers.

PharmGen Science Stock analysis

What does PharmGen Science do? PharmGen Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmGen Science stock

EV/EBIT (Enterprise Value to EBIT) of PharmGen Science is 7.71 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — PharmGen Science

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — PharmGen Science